# PetVivo Holdings, Inc.: overview PETV · OTC · CIK 1512922 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/petv.md) · [Financials](/companies/petv/financials.md) · [Filings](/companies/petv/filings.md) · [Insiders](/companies/petv/insiders.md) Latest reported revenue: [$337.6k](/filings/0001493152-26-038477.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038477). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [201](/filings/0001493152-25-023398.md) | [583](/filings/0001493152-26-007150.md) | [225 d](/filings/0001493152-26-031136.md) | [298](/filings/0001493152-26-038477.md) | [303](/filings/0001493152-25-023398.md) | [286](/filings/0001493152-26-007150.md) | [255 d](/filings/0001493152-26-031136.md) | [338](/filings/0001493152-26-038477.md) | | Gross margin | % | [89.5%](/filings/0001493152-25-023398.md) | [89.5%](/filings/0001493152-26-007150.md) | [81.3% d](/filings/0001493152-26-031136.md) | [62.8%](/filings/0001493152-26-038477.md) | [72.6%](/filings/0001493152-25-023398.md) | [50.6%](/filings/0001493152-26-007150.md) | [79.8% d](/filings/0001493152-26-031136.md) | [66.2%](/filings/0001493152-26-038477.md) | | Operating margin | % | [(1082.6%)](/filings/0001493152-25-023398.md) | [(301.5%)](/filings/0001493152-26-007150.md) | [(925.4%) d](/filings/0001493152-26-031136.md) | [(619.9%)](/filings/0001493152-26-038477.md) | [(681.0%)](/filings/0001493152-25-023398.md) | [(766.0%)](/filings/0001493152-26-007150.md) | [(1162.8%) d](/filings/0001493152-26-031136.md) | [(476.6%)](/filings/0001493152-26-038477.md) | | Net margin | % | [(1083.8%)](/filings/0001493152-26-007150.md) | [(301.2%)](/filings/0001493152-26-007150.md) | [(1076.6%) d](/filings/0001493152-26-031136.md) | [(776.8%)](/filings/0001493152-26-038477.md) | [(991.7%)](/filings/0001493152-26-007150.md) | [(766.0%)](/filings/0001493152-26-007150.md) | [(1163.4%) d](/filings/0001493152-26-031136.md) | [(478.1%)](/filings/0001493152-26-038477.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001493152-25-023398.md) | [(0.09)](/filings/0001493152-26-007150.md) | not reported | [(0.10)](/filings/0001493152-26-038477.md) | [(0.11)](/filings/0001493152-25-023398.md) | [(0.07)](/filings/0001493152-26-007150.md) | not reported | [(0.05)](/filings/0001493152-26-038477.md) | | Free cash flow | $k | [(1,604) d](/filings/0001493152-25-023398.md) | [(985) d](/filings/0001493152-26-007150.md) | [(1,251) d](/filings/0001493152-26-031136.md) | not reported | not reported | [(1,472) d](/filings/0001493152-26-007150.md) | [(812) d](/filings/0001493152-26-031136.md) | [(978)](/filings/0001493152-26-038477.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [116](/filings/0001493152-23-022907.md) | [917](/filings/0001493152-24-025637.md) | [969](/filings/0001641172-25-018617.md) | [1,133](/filings/0001493152-26-031136.md) | [1,142](/filings/0001493152-26-031136.md) | | Gross margin | % | [(74.0%)](/filings/0001493152-23-022907.md) | [75.9%](/filings/0001493152-24-025637.md) | [89.5%](/filings/0001641172-25-018617.md) | [87.8%](/filings/0001493152-26-031136.md) | [66.1%](/filings/0001493152-26-031136.md) | | Operating margin | % | [(4374.7%)](/filings/0001493152-23-022907.md) | [(952.2%)](/filings/0001493152-24-025637.md) | [(1096.4%)](/filings/0001641172-25-018617.md) | [(711.3%)](/filings/0001493152-26-031136.md) | [(793.9%)](/filings/0001493152-26-031136.md) | | Net margin | % | [(4338.8%)](/filings/0001493152-23-022907.md) | [(950.5%)](/filings/0001493152-24-025637.md) | [(1130.9%)](/filings/0001641172-25-018617.md) | [(741.6%)](/filings/0001493152-26-031136.md) | [(917.4%)](/filings/0001493152-26-031136.md) | | Diluted EPS | $ per share | not reported | [(0.85)](/filings/0001493152-24-025637.md) | [(0.78)](/filings/0001641172-25-018617.md) | [(0.41)](/filings/0001493152-26-031136.md) | [(0.38)](/filings/0001493152-26-031136.md) | | Free cash flow | $k | [(4,329)](/filings/0001493152-23-022907.md) | [(7,218)](/filings/0001493152-24-025637.md) | [(7,729)](/filings/0001641172-25-018617.md) | [(5,385)](/filings/0001493152-26-031136.md) | [(6,115)](/filings/0001493152-26-031136.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/petv/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Vermillion Wealth Management, Inc.](/funds/1737012.md) | 2026-06-30 | $40.4k | 48,100 | | New +48,100 | ## Recent filings [All 697 filings](/companies/petv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-22 | 11:00 ET | [8-K](/filings/0001493152-26-043639.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-043639 | | 2026-09-22 | 11:00 ET | [8-K](/filings/0001493152-26-043641.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-043641 | | 2026-09-15 | 20:04 ET | [SCHEDULE 13D/A](/filings/0001099910-26-000264.md) | Ownership report, active investor, amended | 0001099910-26-000264 | | 2026-08-20 | 13:20 ET | [8-K](/filings/0001493152-26-039397.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-039397 | | 2026-08-14 | 20:58 ET | [10-Q](/filings/0001493152-26-038477.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038477 | | 2026-07-29 | 22:10 ET | [8-K](/filings/0001493152-26-035053.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035053 | | 2026-07-27 | 18:28 ET | [8-K](/filings/0001493152-26-034762.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-034762 | | 2026-06-29 | 21:30 ET | [10-K](/filings/0001493152-26-031136.md) | Annual report, period 2026-03-31 | 0001493152-26-031136 | | 2026-06-25 | 21:23 ET | [8-K](/filings/0001493152-26-030193.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030193 | | 2026-06-11 | 22:04 ET | [8-K](/filings/0001493152-26-028172.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-028172 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001493152-26-031136.md), filed Jun 29, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/53d64a0c-02bd-4438-ba67-bd03ddcd3dbc) ## About the filer - CIK: 1512922 - Tickers: PETV - Exchange: OTC - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: NV - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.